Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery
Highlights Summary iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole or placebo for